ZA200005961B - Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia. - Google Patents

Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia.

Info

Publication number
ZA200005961B
ZA200005961B ZA200005961A ZA200005961A ZA200005961B ZA 200005961 B ZA200005961 B ZA 200005961B ZA 200005961 A ZA200005961 A ZA 200005961A ZA 200005961 A ZA200005961 A ZA 200005961A ZA 200005961 B ZA200005961 B ZA 200005961B
Authority
ZA
South Africa
Prior art keywords
benzothiophenes
benzofurans
hyperglycemia
treatment
insulin resistance
Prior art date
Application number
ZA200005961A
Inventor
Jay Edward Wrobel
Arlene Joan Dietrich
Madelene Miyoko Antane
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of ZA200005961B publication Critical patent/ZA200005961B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
ZA200005961A 1998-05-12 2000-10-24 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia. ZA200005961B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7671298A 1998-05-12 1998-05-12

Publications (1)

Publication Number Publication Date
ZA200005961B true ZA200005961B (en) 2001-10-24

Family

ID=22133746

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200005961A ZA200005961B (en) 1998-05-12 2000-10-24 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia.

Country Status (22)

Country Link
EP (1) EP1077969A1 (en)
JP (1) JP2002516321A (en)
KR (1) KR20010043539A (en)
CN (1) CN1308626A (en)
AR (1) AR015294A1 (en)
AU (1) AU756337B2 (en)
BG (1) BG104918A (en)
BR (1) BR9911779A (en)
CA (1) CA2330620A1 (en)
EA (1) EA200001175A1 (en)
EE (1) EE200000653A (en)
HR (1) HRP20000767A2 (en)
HU (1) HUP0101792A3 (en)
ID (1) ID26244A (en)
IL (1) IL139132A0 (en)
NO (1) NO20005677L (en)
PL (1) PL344081A1 (en)
SK (1) SK16992000A3 (en)
TR (1) TR200003333T2 (en)
TW (1) TW510900B (en)
WO (1) WO1999061435A1 (en)
ZA (1) ZA200005961B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018363A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
WO2002026707A1 (en) * 2000-09-26 2002-04-04 Biovitrum Ab Novel compounds
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
US20030013709A1 (en) * 2001-06-07 2003-01-16 Wyeth Combination of a PTPase inhibitor and an alpha-glucosidase inhibitor
WO2002098510A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination of a ptpase inhibitor and an aldose reductase inhibitor
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
WO2002098414A1 (en) * 2001-06-07 2002-12-12 Wyeth Methods using ptpase inhibitors and insulin
WO2002098409A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination therapy for type ii diabetes or syndrome x
AR034374A1 (en) * 2001-06-07 2004-02-18 Wyeth Corp COMBINATION OF A PTPASA INHIBITOR AND AN ACE INHIBITOR
WO2002100397A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
US20030022896A1 (en) * 2001-06-07 2003-01-30 Wyeth PTPase inhibitors for improving cardiovascular risk profile
AR034375A1 (en) * 2001-06-07 2004-02-18 Wyeth Corp COMBINATION OF A PTPASA INHIBITOR AND A SULFONILE AGENT
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003032982A1 (en) * 2001-10-19 2003-04-24 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
WO2003048140A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
ITMI20022172A1 (en) * 2002-10-14 2004-04-15 Clariant Lsm Italia Spa PROCESS FOR THE PREPARATION OF 3-ALCHYL-THIOPHENI-2, 5-REPLACED.
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA05006287A (en) 2002-12-10 2005-09-08 Wyeth Corp Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1).
CA2509191A1 (en) 2002-12-10 2004-06-24 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052853A2 (en) 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1726190A (en) 2002-12-10 2006-01-25 惠氏公司 Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
JPWO2004106542A1 (en) 2003-05-29 2006-07-20 三共株式会社 Insulin resistance improving agent and screening method thereof
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
FR2862645B1 (en) * 2003-11-20 2007-06-22 Merck Sante Sas ANTIDIABETIC COMPOUNDS CONTAINING BENZOFURAN, BENZOTHIOPHENIC DERIVATIVES
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
RU2007106868A (en) 2004-08-23 2008-09-27 Вайет (Us) Oxazole-naphthyl acids and their use as modulators of an inhibitor of plasminogen-1 (PAI) activator for the treatment of thrombosis and cardiovascular diseases
EP1919866A2 (en) 2005-08-17 2008-05-14 Wyeth a Corporation of the State of Delaware Substituted indoles and use thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
GB0822486D0 (en) * 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014142364A2 (en) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
CN106749169B (en) * 2016-11-07 2020-04-21 浙江工业大学 Chiral preparation method of Ertiprotafib
CN107033122B (en) * 2017-05-19 2019-06-14 南方医科大学 A kind of N- aryl -2- thiophene-carboxamides analog derivative and its preparation method and application
EP3792345A4 (en) 2018-04-26 2022-02-23 Tokyo Institute of Technology Method for promoting differentiation of pluripotent stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE344748B (en) * 1968-08-15 1972-05-02 Parke Davis & Co
US3639422A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 4-phenylindole-1 (and 7)-acetic acids
US3682976A (en) * 1970-02-16 1972-08-08 Parke Davis & Co Phenyl benzofuran acetic acid compounds
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
FR2599740B1 (en) * 1986-06-05 1988-08-12 Rhone Poulenc Sante BENZO (B) THIOPHENE DERIVATIVES OF BENZO (B) FURANNECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM
JPH01135766A (en) * 1987-11-20 1989-05-29 Tanabe Seiyaku Co Ltd Biphenyl derivative
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
DE4425613A1 (en) * 1994-07-20 1996-01-25 Bayer Ag 5-membered heteroaryl oxazolidinones

Also Published As

Publication number Publication date
JP2002516321A (en) 2002-06-04
SK16992000A3 (en) 2001-04-09
ID26244A (en) 2000-12-07
AU3893999A (en) 1999-12-13
HUP0101792A3 (en) 2003-01-28
CA2330620A1 (en) 1999-12-02
PL344081A1 (en) 2001-09-24
EE200000653A (en) 2002-04-15
TW510900B (en) 2002-11-21
AR015294A1 (en) 2001-04-18
TR200003333T2 (en) 2001-02-21
BR9911779A (en) 2001-02-06
EP1077969A1 (en) 2001-02-28
BG104918A (en) 2001-08-31
HRP20000767A2 (en) 2001-10-31
CN1308626A (en) 2001-08-15
NO20005677D0 (en) 2000-11-10
EA200001175A1 (en) 2001-06-25
HUP0101792A2 (en) 2002-01-28
AU756337B2 (en) 2003-01-09
WO1999061435A1 (en) 1999-12-02
IL139132A0 (en) 2001-11-25
NO20005677L (en) 2000-12-05
KR20010043539A (en) 2001-05-25

Similar Documents

Publication Publication Date Title
ZA200005961B (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia.
AU4072799A (en) 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
AU3979199A (en) 11-aryl-benzo{b}naphtho{2,3-d}furans and 11-aryl-benzo{b}naphtho{2,3-d}thiophenes useful in the treatment of insulin resistance and hyperglycemia
ZA200201806B (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof.
ZA978455B (en) Use of leptin antagonists for treating insulin resistance in type II diabetes.
IL143102A0 (en) 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
ZA983148B (en) Modified TNFÓ, DNA encoding such modified TNFÓ and vacines comprising said TNFÓ and DNA.
PL344346A1 (en) Platinum complex, its preparation and therapeutic application
MXPA02001613A (en) Tissue augmentation material and methods.
ZA985546B (en) Treatment of insulin resistance.
AU2776199A (en) Treating wastes, preparing construction materials and stabilizing
ZA200204374B (en) Pre-filled syringe and method for making same.
ZA200001746B (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use.
AU7896100A (en) Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
EP1210084A4 (en) Pyridomorphinans, thienomoprhinans and use thereof
PL344345A1 (en) Platinum complex, its preparation and therapeutic application
EP1117675A4 (en) Cadherin-like asymmetry protein-1, and methods for its use
ZA200000145B (en) Melting furnace, in particular for glass and use thereof.
HK1032913A1 (en) Ophthalmic solution comprising glycogen.
GB9820631D0 (en) Hair treatment composition, method and use
AP2006003504A0 (en) Outer surface proteins, their genes, and their use.
ZA997490B (en) High hardness and strength sintered body.
ZA200001747B (en) 3-Amino-3-arylpropan-1-ol derivatives, their preparation and use.
MXPA02002203A (en) Diolefin hydroxyaryl condensates and catalyst therefor.
HK1045942A1 (en) Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics